Jazz Pharmaceuticals registers Phase 2/3 trial of JZP926 for juvenile myoclonic epilepsy
A single new study record shows Jazz testing JZP926 capsules against placebo in patients 10 and older with juvenile myoclonic epilepsy.
Jazz Pharmaceuticals has one notable registry update this week, a Phase 2/3 study of its cannabinoid candidate JZP926.
- JZP926 capsule, a Phase 2/3 drug, is being tested in Juvenile Myoclonic Epilepsy (JME) and is listed as recruiting as of October 6, 2026. The study measures change from baseline in myoclonic seizure days per 28 days during the 16-week treatment period as its primary outcome1, with planned enrollment of 260 participants1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.